Shuttle Pharmaceuticals
SHPH
3 hedge funds and large institutions have $49.2K invested in Shuttle Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 5 closing their positions.
0.72% less ownership
Funds ownership: 0.99% → 0.27% (-0.72%)
63% less funds holding
Funds holding: 8 → 3 (-5)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $191K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
-$33K |
| 2 |
Two Sigma Securities
New York
|
-$32.3K |
| 3 |
Virtu Financial
New York
|
-$31K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$28.7K |
| 5 |
Goldman Sachs
New York
|
-$24.4K |
SHPH Hedge Fund Activity: Q1 2023 in Review
3 of the 6,290 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q1 2023, worth a combined $49.2K — down 81% from $265K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SHPH and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was SG Americas Securities, exiting entirely with an estimated $33K sold.
- 3 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q1 2023, down from 8 in Q4 2022.
- Funds reported $49.2K of Shuttle Pharmaceuticals stock for Q1 2023, down 81% quarter-over-quarter.
- 0 funds opened new Shuttle Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of -5 holders.
- The largest Shuttle Pharmaceuticals seller in Q1 2023 was SG Americas Securities, an estimated $33K sold.
Based on aggregated 13F filings for Q1 2023.